RimonabantCB1 receptor antagonist CAS# 168273-06-1 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 168273-06-1 | SDF | Download SDF |
| PubChem ID | 104850 | Appearance | Powder |
| Formula | C22H21Cl3N4O | M.Wt | 463.79 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | SR141716 | ||
| Solubility | Soluble in DMSO > 10 mM | ||
| Chemical Name | 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide | ||
| SMILES | CC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl | ||
| Standard InChIKey | JZCPYUJPEARBJL-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C22H21Cl3N4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Rimonabant(SR141716) is a selective central cannabinoid (CB1) receptor inverse agonist with Ki of 1.8 nM.
IC50 Value: 1.8 nM(Ki)
Target: CB1 Receptor
in vitro: Rimonabant dose-dependently reduces ACAT activity in Raw264.7macrophages with IC50 of 2.9 μM and isolated peritoneal macrophages. Rimonabant inhibits ACATactivity in intact CHO-ACAT1 and CHO-ACAT2 cells and in cell-free assays with approximately equal efficiency with IC50 of 1.5 μM and 2.2 μM for CHO-ACAT1 and CHO-ACAT2, respectively. Consistent with ACAT inhibition, Rimonabant treatment blocks ACAT dependent processes in macrophages, oxysterol-induced apoptosis and acetylated-LDL induced foam cell formation. Rimonabant antagonizes the inhibitory effects of cannabinoid receptor agonists on both mouse vas deferens contractions and adenylyl cyclase activity in rat brain membranes in a concentration-dependent manner.
in vivo: Rimonabant (10 mg/kg by gavage) is fed for 2 weeks to 3-month-old male obese Zucker rats as an impaired glucose tolerance model and for 10 weeks to 6-month-old male obese Zucker rats as a model of the metabolic syndrome. RANTES (Regulated upon Activation, Normal T cell Expressed, and Secreted) and MCP-1 (monocyte chemotactic protein-1) serum levels are increased in obese vs lean Zucker rats and significantly reduced by long-term treatment with Rimonabant, which slowes weight gain in rats with the metabolic syndrome. Neutrophils and monocytes are significantly increased in young and old obese vs lean Zucker rats and lowered by Rimonabant. Platelet-bound fibrinogen is significantly enhanced in obese vs lean Zucker rats of both age, and is reduced by Rimonabant. Platelets from obese rats are more sensitive to thrombin-induced aggregation and adhesion to fibrinogen, which are both attenuated by Rimonabant therapy. References: | |||||
Rimonabant Dilution Calculator
Rimonabant Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.1561 mL | 10.7807 mL | 21.5615 mL | 43.123 mL | 53.9037 mL |
| 5 mM | 0.4312 mL | 2.1561 mL | 4.3123 mL | 8.6246 mL | 10.7807 mL |
| 10 mM | 0.2156 mL | 1.0781 mL | 2.1561 mL | 4.3123 mL | 5.3904 mL |
| 50 mM | 0.0431 mL | 0.2156 mL | 0.4312 mL | 0.8625 mL | 1.0781 mL |
| 100 mM | 0.0216 mL | 0.1078 mL | 0.2156 mL | 0.4312 mL | 0.539 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Rimonabant (SR141716) is a potent and selective antagonist of central cannabinoid (CB1) receptor with Ki values of 1.8nM and 514nM for CB1 and CB2, respectively [1].
Rimonabant (SR141716) has shown a 285–fold CB1 selectivity (Ki=1.8nM CB1, 514nM CB2). The affinity of Rimonabant for CB1-Rs is 50-fold higher than for CB2-Rs with a Ki value of 6.18nM for CB1-Rs [1]. In addition, Rimonabant has been revealed to produce changes in ingestive behaviors when treatment alone. Moreover Rimonabant has been reported to selectively reduce the consumption of palatable food and drink. Rimonabant has also been noted to decrease sucrose intake in rat, alcohol consumption in mice and sweet diet intake in marmosets when having little effect on bland food consumption [2].
References:
[1]Soudijn W1, van Wijngaarden I, Ijzerman AP. Structure-activity relationships of inverse agonists for G-protein-coupled receptors. Med Res Rev. 2005 Jul;25(4):398-426.
[2] Ravinet Trillou C1, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, Soubrie P. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol. 2003 Feb;284(2):R345-53. Epub 2002 Oct 24.
- Evofolin B
Catalog No.:BCN1101
CAS No.:168254-96-4
- Wilforol C
Catalog No.:BCN1100
CAS No.:168254-95-3
- Nortenuazonic acid
Catalog No.:BCN1847
CAS No.:16820-44-3
- Agitoxin 2
Catalog No.:BCC8026
CAS No.:168147-41-9
- Taxin B
Catalog No.:BCN6945
CAS No.:168109-52-2
- Mearnsetin
Catalog No.:BCN6560
CAS No.:16805-10-0
- cis-Miyabenol C
Catalog No.:BCN3347
CAS No.:168037-22-7
- Boc-D-Threoninol(Bzl)
Catalog No.:BCC2703
CAS No.:168034-31-9
- NXY-059
Catalog No.:BCC4955
CAS No.:168021-79-2
- Triptonine B
Catalog No.:BCN3095
CAS No.:168009-85-6
- Otophylloside B 4'''-O-beta-D-oleandropyranoside
Catalog No.:BCN7512
CAS No.:168001-54-5
- Stigmasta-4,22-diene-3beta,6beta-diol
Catalog No.:BCN1533
CAS No.:167958-89-6
- 3,5-Dimethoxy-3'-hydroxybibenzyl
Catalog No.:BCN8112
CAS No.:168281-05-8
- C-Veratroylglycol
Catalog No.:BCN1102
CAS No.:168293-10-5
- 3-O-Acetyl-16 alpha-hydroxytrametenolic acid
Catalog No.:BCN1532
CAS No.:168293-13-8
- 3-O-Acetyl-16 alpha-hydroxydehydrotrametenolic acid
Catalog No.:BCN1531
CAS No.:168293-14-9
- 3-Epidehydropachymic acid
Catalog No.:BCN3644
CAS No.:168293-15-0
- Asiaticoside
Catalog No.:BCN1011
CAS No.:16830-15-2
- Oxymatrine
Catalog No.:BCN1103
CAS No.:16837-52-8
- Tacrine hydrochloride
Catalog No.:BCC6869
CAS No.:1684-40-8
- Compound 401
Catalog No.:BCC7622
CAS No.:168425-64-7
- Rhodiocyanoside A
Catalog No.:BCN7852
CAS No.:168433-86-1
- Epifriedelanol
Catalog No.:BCN1104
CAS No.:16844-71-6
- SHU 9119
Catalog No.:BCC6019
CAS No.:168482-23-3
Post-sensitization treatment with rimonabant blocks the expression of cocaine-induced behavioral sensitization and c-Fos protein in mice.[Pubmed:28366798]
Pharmacol Biochem Behav. 2017 May;156:16-23.
CB1 receptor antagonists have been shown to prevent acute and long-term behavioral effects of cocaine. Here we evaluate the effectiveness of the CB1 receptor antagonist Rimonabant to modify sensitized responses to cocaine. Mice were treated with saline or cocaine injections in a 15-day intermittent sensitization treatment and subsequently treated with either vehicle, 1 or 10mg/kg Rimonabant in the drug-associated environment for 8 consecutive days. Animals were then challenged with saline and cocaine in the open-field apparatus on subsequent days to evaluate the expression of conditioned and sensitized effects to cocaine. c-Fos protein expression was evaluated in the nucleus accumbens (NAcc), ventral tegmental area (VTA), basolateral amygdala (BLA), medial prefrontal cortex (mPFC) and caudate-putamen (CPu) after the last (cocaine) challenge. Previous treatment with 10mg/kg Rimonabant blocked the expression of conditioned hyperlocomotion and behavioral sensitization to cocaine, but not acute cocaine-induced hyperlocomotion. These behavioral effects were accompanied by significant changes in c-Fos expression in the brain reward system. Chronic cocaine sensitization blunted a subsequent acute cocaine-induced increase in c-Fos protein in the NAcc, effect that was reversed by previous treatment with Rimonabant. Treatment with 10mg/kg Rimonabant also attenuated the significant increase in c-Fos expression in the CPu, mPFC and BLA induced by previous chronic sensitization with cocaine. Our findings add to the evidence that drugs targeting CB1 receptors are good candidates for the treatment of cocaine abuse and provide further insights into the mechanisms underlying endocannabinoid signaling within the brain reward system in the context of cocaine abuse.
The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability.[Pubmed:27493155]
Int J Neuropsychopharmacol. 2016 Dec 30;19(12). pii: pyw068.
BACKGROUND: Multiple studies suggest a pivotal role of the endocannabinoid system in regulating the reinforcing effects of various substances of abuse. Rimonabant, a CB1 inverse agonist found to be effective for smoking cessation, was associated with an increased risk of anxiety and depression. Here we evaluated the effects of the CB1 neutral antagonist AM4113 on the abuse-related effects of nicotine and its effects on anxiety and depressive-like behavior in rats. METHODS: Rats were trained to self-administer nicotine under a fixed-ratio 5 or progressive-ratio schedules of reinforcement. A control group was trained to self-administer food. The acute/chronic effects of AM4113 pretreatment were evaluated on nicotine taking, motivation for nicotine, and cue-, nicotine priming- and yohimbine-induced reinstatement of nicotine-seeking. The effects of AM4113 in the basal firing and bursting activity of midbrain dopamine neurons were evaluated in a separate group of animals treated with nicotine. Anxiety/depression-like effects of AM4113 and Rimonabant were evaluated 24h after chronic (21 days) pretreatment (0, 1, 3, and 10mg/kg, 1/d). RESULTS: AM4113 significantly attenuated nicotine taking, motivation for nicotine, as well as cue-, priming- and stress-induced reinstatement of nicotine-seeking behavior. These effects were accompanied by a decrease of the firing and burst rates in the ventral tegmental area dopamine neurons in response to nicotine. On the other hand, AM4113 pretreatment did not have effects on operant responding for food. Importantly, AM4113 did not have effects on anxiety and showed antidepressant-like effects. CONCLUSION: Our results indicate that AM4113 could be a promising therapeutic option for the prevention of relapse to nicotine-seeking while lacking anxiety/depression-like side effects.
Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors.[Pubmed:28097916]
J Enzyme Inhib Med Chem. 2017 Dec;32(1):444-451.
Cannabinoid (CB) and opioid systems are both involved in analgesia, food intake, mood and behavior. Due to the co-localization of micro-opioid (MOR) and CB1 receptors in various regions of the central nervous system (CNS) and their ability to form heterodimers, bivalent ligands targeting to both these systems may be good candidates to investigate the existence of possible cross-talking or synergistic effects, also at sub-effective doses. In this work, we selected from a small series of new Rimonabant analogs one CB1R reverse agonist to be conjugated to the opioid fragment Tyr-D-Ala-Gly-Phe-NH2. The bivalent compound (9) has been used for in vitro binding assays, for in vivo antinociception models and in vitro hypothalamic perfusion test, to evaluate the neurotransmitters release.
Rimonabant, a selective cannabinoid1 receptor antagonist, protects against light-induced retinal degeneration in vitro and in vivo.[Pubmed:28315677]
Eur J Pharmacol. 2017 May 15;803:78-83.
The endocannabinoid system is involved in some neurodegenerative diseases such as Alzheimer's disease. An endogenous constellation of proteins related to cannabinoid1 receptor signaling, including free fatty acids, diacylglycerol lipase, and N-acylethanolamine-hydrolyzing acid amidase, are localized in the murine retina. Moreover, the expression levels of endogenous agonists of cannabinoid receptors are changed in the vitreous fluid. However, the role of the endocannabinoid system in the retina, particularly in the light-induced photoreceptor degeneration, remains unknown. Therefore, we investigated involvement of the cannabinoid1 receptor in light-induced retinal degeneration using in vitro and in vivo models. To evaluate the effect of cannabinoid1 receptors in light irradiation-induced cell death, the mouse retinal cone-cell line (661W) was treated with a cannabinoid1 receptor antagonist, Rimonabant. Time-dependent changes of expression and localization of retinal cannabinoid1 receptors were measured using Western blot and immunostaining. Retinal damage was induced in mice by exposure to light, followed by intravitreal injection of Rimonabant. Electroretinograms and histologic analyses were performed. Rimonabant suppressed light-induced photoreceptor cell death. Cannabinoid1 receptor expression was upregulated by light exposure. Treatment with Rimonabant improved both a- and b-wave amplitudes and the thickness of the outer nuclear layer. These results suggest that the cannabinoid1 receptor is involved in light-induced retinal degeneration and it may represent a therapeutic target in the light-induced photoreceptor degeneration related diseases.
